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Thrombosed arteriovenous fistula for hemodialysis access is
characterized by a marked inflammatory activity.
Background. Thrombosis is the dominant cause of failure
of arteriovenous fistulas for hemodialysis access. Vascular in-
flammation, an important pathologic change in various human
vascular diseases, may be involved in the thrombotic process of
arteriovenous fistulas.
Methods. The inflammatory activities of 23 thrombosed
and 13 nonthrombosed stenotic arteriovenous fistulas were
compared by investigating the contents of macrophages
and lymphocytes, and the expression of intercellular adhe-
sion molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1), tumor necrosis factor-a (TNF-a), and interleukin-6
(IL-6) using immunohistochemistry method. The expression of
matrix metalloproteinase (MMP)-2 and MMP-9, which play im-
portant roles in thrombosis of human coronary artery, was also
investigated. The immunoreaction results were characterized
using a semiquantitative scoring system.
Results. The macrophage and lymphocyte contents of the
thrombosed group were abundant, and markedly greater than
those of the nonthrombosed group (P < 0.001 and P = 0.001, re-
spectively). The infiltration of macrophages and neovasculature
were spatially closely correlated. The expressions of VCAM-1,
IL-6, and TNF-a, but not ICAM-1, were significantly higher in
the thrombosed group (P = 0.031, P = 0.010, P < 0.001, and P =
1.000, respectively). The expression of MMP-2 was not different
in either groups (P = 0. 344). Differential expression of MMP-9
by macrophages near the vascular lumen, but not those distant
from the lumen, was observed in most thrombosed specimens.
Conclusion. This study demonstrated that the thrombosed
arteriovenous fistula was characterized by marked inflamma-
tion. We hypothesize that the preferential expression of MMP-
9 at luminal edge may cause disruption of the anticoagulant
endothelial barrier and contribute to luminal thrombosis of ar-
teriovenous fistulas.
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Hemodialysis vascular access failure is the dominant
cause of morbidity and the major cost of care for end-
stage renal disease (ESRD) patients [1–4]. Substantial
previous studies demonstrated that in more than 80% of
the vascular access failures the cause is vascular throm-
bosis superimposed on preexisting stenosis at the ve-
nous outflow of the arteriovenous fistula [5–9]. Surgical
thrombectomy remains the standard treatment for sal-
vage of the thrombosed arteriovenous fistulas. However,
the mid- or long-term patency rate after thrombectomy
is unsatisfactory [10–13]. Any attempt to improve the ef-
ficacy of the treatment requires further understanding
of the vascular pathology of thrombosed arteriovenous
fistulas.
The importance of inflammation in the development of
various vascular diseases in both the general population
and the uremic patients is gaining increasing apprecia-
tion. Thrombotic events in human coronary artery [14, 15]
and deep vein of limbs [16–19] have been shown to be as-
sociated with inflammation of affected vessels. In human
arteriovenous fistulas, inflammation may also be involved
in the process of thrombosis. In the Canadian Hemodialy-
sis Morbidity Study, hypoalbuminemia was the strongest
predictor of arteriovenous graft thrombosis [20]. It is now
well accepted that hypoalbuminemia is not only an indi-
cator of malnutrition in uremic patients but also occurs as
a result of inflammation [21–24]. These observations in-
directly support that inflammation might play some role
in the thrombosis of arteriovenous fistulas.
Accordingly, this study compared the inflammatory
activity of the venous segment of thrombosed ver-
sus nonthrombosed arteriovenous fistulas by examin-
ing the infiltration of macrophages and lymphocytes,
and the expression of inflammation-associated molecules,
including the adhesion molecules, intercellular adhe-
sion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1), and proinflammatory cytokines,
interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a)
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Table 1. Clinical characteristics of study subjects
Patient Cause of Duration of Life of Cause of
number Age years Gender revision ESRD months access months ESRD/major comorbidity
1 18 M Primary stenosis 6 6 Chronic glomerulonephritis/nil
2 51 F Primary stenosis 16 16 Unknown/nil
3 47 F Primary stenosis 3 3 Unknown/hypertension
4 65 M Primary stenosis 14 14 Renal artery stenosis/nil
5 52 M Primary stenosis 28 28 Diabetes/nil
6 69 M Primary stenosis 12 12 Unknown/nil
7 69 F Primary stenosis 2 2 Unknown/nil
8 22 F Primary stenosis 24 24 Chronic glomerulonephritis/nil
9 64 M Primary stenosis 2 2 Chronic glomerulonephritis/nil
10 71 M Primary stenosis 6 6 Unknown/nil
11 33 F Primary stenosis 10 10 Chronic glomerulonephritis/nil
12 55 F Primary stenosis 8 8 Unknown/hypertension
13 62 M Primary stenosis 9 9 Diabetes/nil
14 55 M Acute thrombosis 36 36 Unknown/nil
15 39 M Acute thrombosis 10 10 Unknown/nil
16 58 M Acute thrombosis 4 4 Unknown/nil
17 46 M Acute thrombosis 6 6 Unknown/nil
18 70 M Acute thrombosis 2 2 Unknown/hypertension
19 39 M Acute thrombosis 84 5 Unknown/hypertension
20 41 M Acute thrombosis 7 6 Diabetes/nil
21 72 M Acute thrombosis 42 37 Unknown/nil
22 67 M Acute thrombosis 46 46 Unknown/nil
23 46 M Acute thrombosis 43 43 Unknown/gouty arthritis
24 50 M Acute thrombosis 5 4 Unknown/ischemic stroke
25 50 M Acute thrombosis 3 3 Diabetes/hypertension
26 28 F Acute thrombosis 33 33 Systemic lupus erythematosus/nil
27 83 F Acute thrombosis 40 40 Unknown/hypertension
28 63 M Acute thrombosis 55 55 Diabetes/hypertension
29 77 F Acute thrombosis 40 40 Unknown/hypertension
30 63 M Acute thrombosis 48 18 Diabetes/nil
31 58 M Acute thrombosis 122 74 Unknown/nil
32 30 M Acute thrombosis 41 41 Chronic glomerulonephritis/nil
33 48 M Acute thrombosis 1 1 Obstructive uropathy/coronary artery disease
34 38 F Acute thrombosis 24 24 Unknown/nil
35 56 F Acute thrombosis 28 28 Diabetes/hypertension, congestive heart failure
36 55 M Acute thrombosis 80 80 Diabetes/hpertension
ESRD is end-stage renal disease.
using the immunohistochemistry method. Since in-
creased expression of matrix metalloproteinases (MMPs)
with subsequent extracellular matrix (ECM) dysregula-
tion and loss of the integrity of atheroma is thought to
contribute to thrombus formation in human coronary
artery disease [25–30], the expression of MMP-2 and
MMP-9 was also investigated.
METHODS
Clinical data
From November 2000 to July 2003, 13 nonthrombosed
primary stenotic and 23 thrombosed specimens of effer-
ent veins of Brescia-Cimino fistulas were obtained dur-
ing surgical revision from 36 hemodialysis patients of
Chung Gung Memorial Hospital, Taipei, Taiwan. The
clinical characteristics of the patients were summarized in
Table 1. All the fistulas investigated were radiocephalic.
The thrombosed lesions were obtained from patients who
received revision due to acute occlusion resulting from
thrombosis. The primary stenotic lesions were collected
as the nonthrombosed control from patients who under-
went surgical revision due to an increased venous pres-
sure and/or low flow volume during hemodialysis without
any previous history of thrombosis or receiving percuta-
neous transluminal angioplasty. For the thrombosed le-
sions, the surgical procedures were done within 8 hours
after the patients arrived at the emergency department.
Thrombectomy was performed routinely before the re-
vision procedure. Specimens retrieved from the polyte-
trafluoroethylene (PTFE) graft–interposed fistulas were
excluded. The clinical diagnosis of thrombosis or stenosis
was confirmed by duplex ultrasound in all cases. The spec-
imens were briefly rinsed with normal saline and fixed in
10% formalin immediately after being harvested. The tis-
sues were then embedded in paraffin, processed accord-
ing to conventional technique, and cut into 5 lm thick
sections.
Immunohistochemistry
Serial sections from each specimen were reacted with
mouse antihuman CD68 (Neomarkers, Fremont, CA,
USA) (1:100 dilution) and mouse antihuman CD3e
(Neomarkers) (1:50 dilution) antibodies to identify the
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macrophages and T lymphocytes, and with mouse antihu-
man a-smooth muscle actin (a-SMA) (Sigma Chemical
Co., St. Louis, MO, USA) (1:100 dilution), rabbit antihu-
man von Willebrand factor (vWF) (Dako, Carpinteria,
CA, USA) (1:200 dilution) as the cell markers for smooth
muscle cells (SMCs) and endothelial cells, respectively.
The adjacent sections were reacted with mouse antihu-
man ICAM-1 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) (1:400 dilution), rabbit antihuman VCAM-1
(Santa Cruz Biotechnology) (1:200 dilution), rabbit anti-
human IL-6 (Santa Cruz Biotechnology) (1:200 dilution),
and goat antihuman TNF-a (R&D Systems, Minneapo-
lis, MN, USA) (1:100 dilution), mouse antihuman MMP-
2 (Neomarkers) (1:200 dilution) and rabbit antihuman
MMP-9 (Neomarkers) (1:100 dilution) antibodies.
Single-labeling immunohistochemistry. First, sections
were deparaffinized with xylene and rehydrated in graded
ethanol series. The sections were then microwave-heated
for 10 minutes in a 0.01 mol/L citrate buffer solution
(pH 6.6). After blocking endogenous peroxidase activ-
ity with 3% H2O2, the primary antibodies were applied
for 60 minutes at room temperature. A biotinylated an-
timouse, antirabbit or antigoat secondary antibody was
then applied for 30 minutes, followed by 10 minutes in-
cubation with peroxidase-conjugated streptavidin. The
slides were exposed to 3,3′-diaminobenzidine (DAB) to
obtain a brown reaction product and counterstained with
contrast blue.
Double-labeling immunofluorescence. Double-
labeling immunofluorescence was performed on tissue
sections adjacent to the sections used for single staining
to determine the cell types that express the adhesion
molecules, proinflammatory cytokines, and MMPs. It
was also performed to examine the spatial correlation
of the infiltrated macrophages and neovasculature. The
immunostaining for the first marker was performed
as described above except that a cyanine 3.18 (Cy3)
(Chemicon, Temecula, CA, USA) (1:250 dilution) or
fluorescein isothiocyanate (FITC) (Chemicon) (1:50
dilution)–conjugated secondary antibody was used
instead. Then the sections were washed copiously with
phosphate-buffered saline (PBS) and exposed to the
second primary antibody for 60 minutes. Then a corre-
sponding secondary antibody conjugated to different
fluorochrome was applied.
Confocal laser microscope
Immunofluorescence-labeled sections were examined
by confocal laser scanning microscopy (Leica TCS SP2-
MP System, Mannheim, Germany), equipped with an ar-
gon and helium/neon laser, and fitted with the appropri-
ate filter blocks for detection of Cy3 and FITC fluores-
cence. The images were taken using single or simulta-
neous dual channel scanning and were transformed into
projection views using sets of consecutive single optical
sections. All specimens were examined within 24 hours
after the immunolabeling protocol.
Characterization of leukocyte content
and immunoreaction of vessel wall
The cross-sectional area of each sample was scored for
macrophage and T-lymphocyte contents on a semiquan-
titative scale ranging from 0 to 3 in which 0 indicated ab-
sence of the cell; 1, occasional isolated cells; 2, small focal
clusters of the cell; and 3, large foci or diffuse presence
of the cell.
The immunoreactions of adhesion molecules, proin-
flammatory cytokines, and MMP-2 were also charac-
terized by a semiquantitative immunoreaction scoring
system, which was designed to value the extent and in-
tensity of immunoreaction. The immunoreaction score
was defined as 0, no reaction; 1, the total area of pos-
itive reaction involving less than one third of the total
cross-sectional area; 2, the total area of positive reaction
involving larger than one third but less than two thirds of
the total cross sectional area; and 3, the total area of pos-
itive reaction involving more than two thirds of the total
cross-sectional area. When the intensity of the reaction
was weak, the immunoreaction score was downgraded
by 1. Since the expression of ICAM-1 was limited to the
single-layered luminal or neovascular endothelial cells,
the immunoreaction score for ICAM-1 was estimated by
dividing the total ICAM-1–positive area to the total vWF-
positive area, instead of the total cross-sectional area.
Scoring was performed independently by two investiga-
tors blinded to the clinical characteristics of the samples.
Statistical analyses
Owing to the limited number of observations in each
group, nonparametric statistical analysis was conducted.
Medians of the immunoreaction scores were compared
across groups using the Mann-Whitney test. When com-
paring continuous data among independent groups, the
Mann-Whitney test was used. All P values presented
were two-sided and the level of significance was 0.05.
RESULTS
General observation
The gross histologic findings in both the thrombosed
and nonthrombosed group were similar except that some
platelet-rich luminal thrombosis was occasionally found
in thrombosed specimens but never in the nonthrom-
bosed specimens. In the thrombosed group, a partial loss
of the luminal endothelial layer was often found, which
might partially be attributed to the thrombectomy proce-
dure performed routinely before resection of the stenotic
segments. The intimal layers of all specimens were com-
posed of neointimal tissue, which encroached upon most
Chang et al: Vascular access thrombosis and inflammation 1315
Fig. 1. Representative photomicrographs of the thrombosed (A to D)
and the nonthrombosed (E to H) arteriovenous fistula for vascular ac-
cess demonstrate the leukocytes contents. B, D, F, and H show the higher
magnification of the area indicated by the inset in A, C, E, and G, respec-
tively. (A and B) Abundant CD68-positive macrophages (arrows) infil-
trate into the neointima (N) and media (M) of the thrombosed arteri-
ovenous fistula. (C and D) Several CD3e-positive lymphocytes (arrows)
infiltrate into the neointima of the thrombosed arteriovenous fistula. (E
and F) No CD68-positive cell is found in the neointima or media of the
nonthrombosed arteriovenous fistula. (G and H) No CD3e-positive is
found in the neointima or media of the nonthrombosed arteriovenous
fistula [original magnification (A, C, E, and G) ×100; (B, D, F, and H)
×400].
of the luminal space. In most specimens of both groups,
neovascularization was common in the intimal and media
layers.
Macrophages and lymphocytes infiltration
Macrophages, identified by positive anti-CD68 reac-
tion, were found in all (100%) the thrombosed specimens.
The cell content was abundant and distributed diffusely
or in a large cluster at both the neointima and media
(Fig. 1A and B). Lymphocytes, identified by positive anti-
CD3e reaction, were found in 17 of the 23 (74%) throm-
bosed lesions. The cells distributed in a small to large
cluster mainly in neointima of the specimens (Fig. 1C and
Fig. 2. Representative double-labeling immunoconfocal images of the
thrombosed vascular access demonstrate the spatial correlation of the
infiltrating macrophages and the neovasculature. (A) A cluster of von
Willebrand factor–positive neovasculature (green color, small arrows)
is demonstrates at the lower part of the panel; and the luminal en-
dothelial cells (green color, large arrows) at the upper left. (B) Abun-
dant CD68-positive macrophages (red color, arrowheads) gather at the
lower part of the panel around the location of the neovasculature shown
(A). (C) Superimposed confocal image of higher magnification confirms
that infiltration of the macrophages (red color, arrowheads) is of close
spatial correlation with the neovasculature (green color, small arrows)
[original magnification (A and B) ×200; (C) ×400].
D). In contrast to the thrombosed group, macrophages
and lymphocytes were found in only six and four of
13 (46% and 31%) nonthrombosed specimens, respec-
tively (Fig. 1E to H). In these specimens, isolated lym-
phocytes were found in the intima or media. The scores
for macrophage and lymphocyte content were markedly
higher in the thrombosed group 3.0 vs. 0.5, P < 0.001;
and 1.5 vs. 0, P < 0.001, respectively) than in the non-
thrombosed group. Of interest is that the area of abun-
dant macrophages infiltration was constantly associated
with infiltration of neovasculature at both intima and
media. Double immunofluorescence labeling, observed
by laser confocal microscope, confirmed the spatial
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Fig. 3. Representative photomicrographs of the thrombosed (A, C,
and E) and the nonthrombosed (B, D, and F) arteriovenous fistula
for vascular access demonstrate expressions of adhesion molecules
and proinflammatory cytokines. (A) Strong antivascular adhesion
molecule-1 (anti-VCAM-1) immunoreaction is identified at the neo-
vascular endothelial cells, and smooth muscle cells (SMCs) of neoin-
tima (N) and media (M) of the thrombosed arteriovenous fistula. (B) In
contrast, the anti-VCAM-1 immunoreaction is much weaker in the non-
thrombosed specimen localized to the neovascular endothelial cells and
some medial SMCs. (C) Anti-intercellular adhesion molecule-1 (anti-
ICAM-1) immunoreaction is identified at the neovascular endothelial
cells of the thrombosed arteriovenous fistula. (D) Similar anti-ICAM-
1 immunoreaction is demonstrated in the nonthrombosed specimen.
(E) Strong anti-interleukin-6 (anti-IL-6) immunoreaction is identified
at neovascular endothelial cells, medial SMCs, and extracellular matrix
(ECM) of the thromosed specimen. (F) In the nonthrombosed speci-
men, only a very weak focal anti- IL-6 reaction is shown at the ECM of
media of the nonthrombosed specimen. (G) Positive anti-tumor necro-
sis factor-a (anti-TNF-a) immunoreaction is identified in the neovas-
cular endothelial cells and ECM of the neointima of the thrombosed
specimen. (H) No positive anti-TNF-a is detectable in the nonthrom-
bosed specimen (original magnification ×100).
correlation between infiltration of macrophages and neo-
vasculature (Fig. 2).
Expression of adhesion molecules
Positive immunoreaction for VCAM-1 was found in 20
of the 23 (87%) thrombosed and 10 of the 13 (77%) non-
Fig. 4. Representative immunoconfocal images of anti-CD68 (red
color) and anti-matrix metalloproteinase-9 (anti-MMP-9) (green color)
double labeling in the thrombosed vascular access demonstrate pref-
erential expression of MMP-9 by macrophages nearby the vascular
lumen (A to C) but not those away from the lumen (D to F). (A)
In the neointima (N) nearby the vascular lumen (L), infiltration of
several CD68-positive macrophages (arrows) are shown. (B) Most of
these macrophages are also MMP-9–positive (small arrowheads). (C)
Superimposed image confirms colocalization of both antigens (yellow
color) implicates that most macrophages nearby the vascular lumen
express MMP-9. (D) At the junction of media (M) and neointima dis-
tant from the vascular lumen, infiltration of abundant CD68-positive
macrophages (arrows) are shown. (E) Most macrophages except one
are MMP-9–negative. (F) Superimposed image confirms that most
macrophages distant from the vascular lumen do not express MMP-
9 (original magnification ×600).
thrombosed specimens. Positive labeling was localized to
the luminal and neovascular endothelial cells, and SMCs
of neointima and media in both groups if present. The
staining for VCAM-1 in the thrombosed group was much
more extensive with a stronger intensity in the throm-
bosed group when compared with the nonthrombosed
group (Fig. 3A and B) The immunoreaction score was
significantly higher in the thrombosed group (2.5 vs. 1.0,
P = 0.031). Positive immunoreaction for ICAM-1 was
detected homogeneously on luminal and neovascualar
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Table 2. Scores of leukocyte contents and immunoreaction scores of the thrombosed and nonthrombosed vascular accesses
Macrophage Lymphocyte VCAM-1 ICAM-1 IL-6 TNF-a MMP-2
Thombosed 3.0 (3.0–2.8) 1.5 (0.5–2.0) 2.5 (1.3–3.0) 3.0 (3.0–3.0) 2.5 (1.5–3.0) 1.0 (0–1.5) 2.0 (1.0–2.5)
Nonthrombosed 0.5 (0–1.0) 0 (0–0.5) 1.0 (0.8–1.8) 3.0 (3.0–3.0) 1.0 (0–2.0) ND 1.5 (1.0–2.0)
P value <0.001 0.001 0.031 1.000 0.010 <0.001 0.344
Abbreviations are: VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intercellular adhesion molecule-1; IL-6, interleukin-6; TNF-a, tumor necrosis factor-a;
MMP-2, matrix metalloproteinase-2; ND, not detectable. Values are medians (interquartile range).
endothelial cells with strong intensity in all specimens of
both the thrombosed and nonthombosed groups (Fig. 3C
and D). The immunoreaction scores of both groups were
similar (3.0 vs. 3.0, P = 1.000).
Expression of cytokines
Positive immunoreaction for IL-6 was found in all the
thrombosed (100%) and eight of the 13 (62%) nonthrom-
bosed specimens. Positive staining was localized to the
SMCs and ECM of neointima and media, and neovascula-
ture, if present. The immunoreaction was more extensive
with a stronger intensity in the thrombosed group when
compared with the nonthrombosed group (Fig. 3E and F)
The immunoreaction score was significantly higher in the
thrombosed group when compared with the nonthrom-
bosed group (2.5 vs. 1.0, P = 0.010). Positive immunore-
action for TNF-a was found in 13 of the 23 (57%) throm-
bosed specimens and none of the nonthrombosed group.
The reaction was distributed in a small or large focus and
localized mainly to the ECM of the neointima or media
and rarely to the neovasculature (Fig. 3G and H) The im-
munoreaction score for TNF-a was significantly higher in
the thrombosed group (1.0 vs. 0, P < 0.001).
Expression of MMPs
Positive immunoreaction for MMP-2 was found in all
(100%) the specimens of both the thrombosed and non-
thrombosed groups. The immunostaining was localized
to the SMCs, ECM, and neovasculature of the neoin-
tima and media. The extension and intensity of positive
reaction varied markedly among specimens. The im-
munoreaction scores were similar in both groups (2.0 in
thrombosed group vs. 1.5 in nonthrombosed group) (P =
0.344). The expression of MMP-9 was much more limited
than that of MMP-2. In the nonthrombosed group, posi-
tive reaction was found in only one sample (7%), in which
the reaction was localized to few isolated macrophages
in the neointima. In the thrombosed group, 21 of the
23 (91%) specimens showed positive immunoreaction to
anti-MMP-9. The reaction was localized to few isolated or
a small cluster of cells at the neointima near the vascular
lumen. Double immunolabeling recognized those MMP-
9–positive cells as macrophages. Although macrophages
were abundant and widespread at the neointima and me-
dia of the thrombosed specimens, most macrophages lo-
cated distant from the lumen at the deeper neointima
layer or the media did not express MMP-9. Imaging by
confocal laser microscope confirmed the preferential ex-
pression of MMP-9 (Fig. 4).
The scores for macrophage and lymphocyte contents
and immunoreaction scores for the adhesion molecules,
proinflammatory cytokines, and MMPs are summarized
in Table 2.
DISCUSSION
This study demonstrated infiltration of abundant
macrophages and small to moderate amounts of lympho-
cytes in the vascular wall of thrombosed arteriovenous
fistula accompanied by increased expression of VCAM-1
and proinflammatory cytokines, IL-6 and TNF-a. These
findings indicated a marked inflammatory activity in-
volved in the vascular wall of thrombosed arteriovenous
fistulas.
Surgical thrombectomy is conventionally performed
to treat the thrombosed arteriovenous fistula. Several
new techniques have been reported in attempt to remove
thrombus percutaneously in recent years. However, the
mid- or long-term patency rate after these procedures
remains low [10–13]. The marked inflammatory activity
of the thrombosed arteriovenous fistula may potentially
exert several adverse biologic effects in maintaining the
arteriovenous fistula patent. Intracellular IL-6 was shown
to stimulate proliferation of vascular SMC in a platelet-
derived growth factor (PDGF)–dependent manner [31,
32]. Additionally, VCAM-1 was demonstrated by Oguchi
et al [33] to be involved in the activation of vascular SMCs
and neointimal formation in apolipoprotein E knockout
mice. Increased expression of IL-6 and VCAM-1 in the
thrombosed arteriovenous fistula demonstrated in the
present study may enhance the vascular SMC prolifer-
ation and subsequent progression of neointimal forma-
tion in the thrombosed arteriovenous fistula. Therefore,
inflammatory activity in the thrombosed arteriovenous
fistulas may contribute to the low long-term patency rate
after thrombectomy.
In human coronary artery, inflammation is thought to
contribute to the luminal thrombosis in acute coronary
syndrome [14, 15]. In these events, ulceration or rupture
of the atheromatous plaque with subsequent exposure
of the highly procoagulant subendothelial tissue to the
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circulating blood leads to thrombosis in the vascular lu-
men [15]. The linkage between inflammation and throm-
bus formation was thought to be through the proteolytic
effect of MMPs expressed by macrophages infiltrating
into the atheroma [25–30]. Dysregulation of the ECM
by increased expression of MMPs results in structural
instability and rupture or ulceration of the atheroma.
The underlying pathologic change of the thrombosed ar-
teriovenous fistula differs from that of the thrombosed
coronary artery. The preexisting lesion in thrombosed
arteriovenous fistulas is composed of neointimal hyper-
plasia rather than atherosclerosis. However, the above
mechanism may also be involved in the pathogenesis of
thrombosis in the arteriovenous fistula. In the present
study, preferential expression of MMP-9 by macrophages
near the vascular lumen was demonstrated in the throm-
bosed specimens, which may potentially cause structural
instability of the neointimal layer and subsequent dis-
ruption of the overlying endothelial layer. To observe
the presence of disintegration of superficial neointima
around the focus of MMP-9 expression may provide im-
portant information to validate this hypothesis. However,
thrombectomy performed routinely for the thrombosed
arteriovenous fistula before resection of the stenotic seg-
ments in the present study might result in denudation in
some specimens, and make this observation infeasible.
One other interesting finding in the present study
is the strong spatial correlation between the infiltrat-
ing macrophages and neovasculature. Similar findings
have been demonstrated in the atherosclerotic plaques
of human coronary artery by O’Brien et al [34]. They
found that the intimal neovasculature in human coro-
nary atheroma is strongly associated with increased inti-
mal leukocytes infiltration. In apolipoprotein E–deficient
mice, Moulton et al [35] further demonstrated that the
inhibition of plaque neovasculariztion by angiogenesis
inhibitor reduced macrophage accumulation. These find-
ings suggest that the neovasculature is an important route
for infiltration of leukocytes into the vascular wall and is
a potential target in reducing the inflammation of arteri-
ovenous fistulas.
The clinical implication of this study is that anti-
inflammatory treatment may be helpful to the throm-
bosed arteriovenous fistula in blocking the potential
adverse biologic effects of inflammatory mediators on the
vessel wall and subsequently improve the longevity of the
arteriovenous fistula. Further study to clarify the causal
role of inflammation on thrombosis of arteriovenous fis-
tulas is necessary to decide whether anti-inflammation
could be a potential strategy for prevention of thrombo-
sis of the hemodialysis vascular access.
Reprint requests to Jong-Hwei S. Pang, Ph.D., Graduate Institute of
Clinical Medical Sciences, Chang-Gung University, Fu-Shin Road no 5,
Kwei-Shan, Tao-Yuan, Taiwan 333.
E-mail: jonghwei@mail.cgu.edu.tw
REFERENCES
1. FELDMAN HI, KOBRIN S, WASSERSTEIN A: Hemodialysis vascular ac-
cess morbidity. J Am Soc Nephrol 7:523–535, 1996
2. FELDMAN HI, HELD PJ, HUTCHINSON JT, et al: Hemodialysis vascular
access morbidity in the United States. Kidney Int 43:1091–1096,
1993
3. U.S. RENAL DATA SYSTEM: X. The cost effectiveness of alternative
types of vascular access and the economic cost of ESRD. Am J
Kidney Dis 26:S140–S156, 1995
4. CARLSTON DM, DUNCAN DA, NAESSENS JM, JOHNSON WJ: Hospital-
ization in dialysis patients. Mayo Clin Proc 59:769–775, 1984
5. SCHWAB SJ, BESARAB A, BEATHARD G, et al: National Kidney Foun-
dation DOQI Clinical Practice Guidelines for Hemodialysis Vascu-
lar Access Working Group. Am J Kidney Dis 30 (Suppl 3):S154–
S196, 1997
6. FAN PY, SCHWAB SJ: Vascular access: Concepts for 1990s. J Am Soc
Nephrol 3:1–11, 1992
7. WINDUS DW: Permanent vascular access: A nephrologist’s view. Am
J Kidney Dis 21:457–451, 1993
8. MUNDA R, FIRST R, ALEXANDEER JW, et al: Polytetrafuoroethlene
graft survival in hemodialysis. JAMA 249:219–222, 1983
9. SCHWAB SJ, RAYMOND JR, SAEED M, et al: Prevention of hemodial-
ysis fistula thrombosis: Early detection of venous stenosis. Kidney
Int 36:707–711, 1989
10. HODGES T, FILLINGER M, ZWOLAK R, et al: Longitudinal compari-
son of dialysis access methods: Risk factors for failure. J Vasc Surg
26:1009–1019, 1997
11. OAKES D, SHERCK J, COBB L: Surgical salvage of failed radiocephalic
fistulae: Techniques and results in 29 patients. Kidney Int 53:480–
487, 1998
12. TURMEL-RODRIGUES L, PENGLOAN J, RODRIGUE H, et al: Treatment
of failed native arteriovenous fistulae for hemodialysis by interven-
tional radiology. Kidney Int 57:1124–1140, 2000
13. OVERBOSCH EH, PATTYNAMA PM, AARTS HJ, et al: Occluded
hemodialysis shunts: Dutch multicenter experience with the hydrol-
yser catheter. Radiology 201:485–488, 1996
14. LIBBY P: The molecular bases of the acute coronary syndrome. Cir-
culation 99:1726–1732, 1995
15. LEE R, LIBBY P: The unstable atheroma. Arterioscler Thromb Vasc
Biol 17:1859–1867, 1997
16. WAKEFIELD TW, STRIETER RM, WILKE CA, et al: Venous thombosis-
associated inflammation and attenuation with neutralizing antibod-
ies to cytokines and adhesion molecules. Arterioslcel Thromb Vasc
Biol 15:258–268, 1995
17. ROUMEN-KLAPPE EM, HEIJER MD, VAN UUM SHM, et al: Inflamma-
tory response in the acute phase of deep vein thrombosis. J Vasc
Surg 35:701–706, 2002
18. TSAI AW, CUSHMAN M, ROSMOND WD, et al: Coagulation factors,
inflammation markers, and venous thromboembolism: The longi-
tudinal investigation of thromboembolism etiology (LITE). Am J
Med 113:636–642, 2002
19. MYERS D, WROBLESKI S, LONDY F, et al: New and effective treat-
ment of experimentally induced venous thrombosis with anti-
inflammatory rPSGL-ig. Thrombosis 87:374–382, 2002
20. CHURCHILL DN, TAYLOR DW, COOK RJ, et al: Canadian Hemodial-
ysis Morbidity Study. Am J Kidney Dis 19:214–234, 1992
21. STENVINKEL P, HEIMBURGER O, PAULTRE F, et al: Strong association
between malnutrition, inflammation, and atherosclerosis in chronic
renal failure. Kidney Int 55:1899–1911, 1999
22. KAYSEN GA, DUBIN JA, MULLER HG, et al: The acute-phase response
varies with time and predicts serum albumin levels in hemodialysis
patients. Kidney Int 58:346–352, 2000
23. KAYSEN GA, DON BR: Factors that affect albumin concentration in
dialysis patients and their relationship to vascular disease. Kidney
Int 63 (Suppl 84):S94–S97, 2003
24. BOLOGA RM, LEVINE DM, PARKER TS, et al: Interleukin-6 predicts
hypoalbuminemia, hypocholestremia, and mortality in hemidialysis
patients. Am J Kidney Dis 32:107–114, 1998
25. GALIS ZS, SUKHOVA GK, LARK MW, LIBBY P: Increased expres-
sion of matrix metalloproteinase and matrix degrading activity in
vulnerable regions of human atherosclerotic plaque. J Clin Invest
94:2493–2503, 1994
Chang et al: Vascular access thrombosis and inflammation 1319
26. LI Z, LI L, ZIELKE HR, et al: Increased expression of 72-kd type IV
collagenase (MMP-2) in human aortic atherosclerotic lesions. Am
J Pathol 148:121–128, 1996
27. KAI H, IKEDA H, YASUKAWA H, et al: Peripheral blood levels of
matrix metalloproteinase-2 and -9 are eleated in patients with acute
coronary syndromes. J Am Coll Cardiol 32:368–372, 1998
28. VAN DER WAL AC, BECKER AE, VAN DER LOOS CM, DAS PK: Site of
intimal rupture or erosion of thrombosed coronary atherosclerotic
plaques is characterized by an inflammatory process irrespective of
the dominant plaque morphology. Circulation 89:36–44, 1994
29. FALK E, SHAH PK, FUSTER V: Coronary plaque disruption. Circula-
tion 92:657–671, 1995
30. BURKE A, FARB A, MALCOM G, et al: Coronary risk factors and
plaque morphology in men with coronary disease who die suddenly.
N Engl J Med 336:1276–1281, 1997
31. IKEDA U, IKEDA M, OOHARA A, et al: Interleukin 6 stimulates growth
of vascular smooth muscle cells in a PDGF-dependent manner. Am
J Physiol 260 (5 Pt 2):H1713–H1717, 1991
32. ROTH M, NAUCK M, TAMM M, et al: Intracellular interleukin 6
mediates platelet-derived growth factor-induced proliferation of
nontransformed cells. Proc Natl Acad Sci USA 92:1312–1316,
1995
33. OGUCHI S, DIMAYUGA P, ZHU J, et al: Monoclonal antibody against
vascular cell adhesion molecule-1 inhibits neointimal formation
after periadventitial carotid artery injury in genetically hyperc-
holesterolemic mice. Arterioscler Thromb Vasc Biol 20:1729–1736,
2000
34. O’BRIEN KD, MCDONALD TO, CHAIT A, et al: Neovascular expres-
sion of E-selectin, intercellular adhesion molecule-1, and vascu-
lar cell adhesion molecule-1 in human atherosclerosis and their
relation to intimal leukocyte content. Circulation 93:672–682,
1996
35. MOULTON KS, VAKILI K, ZURAKOWSKI D, et al: Inhibition of plaque
neovascularization reduces macrophage accumulation and progres-
sion of advanced atheroeclerosis. Proc Natl Acad Sci USA 100:4736–
4741, 2003
